LAUNXP Biomedical Co., Ltd (TPEX:6876)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
19.90
-0.60 (-2.93%)
Apr 29, 2026, 2:00 PM CST
15.03%
Market Cap 642.60M
Revenue n/a
Net Income n/a
Shares Out 32.45M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 429,452
Average Volume 329,294
Open 20.20
Previous Close 20.50
Day's Range 18.50 - 20.50
52-Week Range 17.00 - 27.00
Beta 0.06
RSI 36.88
Earnings Date n/a

About LAUNXP Biomedical

LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6876
Full Company Profile

News

There is no news available yet.